sqz biotechnologies stock price

SQZ Biotechnologies has a beta of 373 indicating that its stock price is 273 more volatile than the SP 500. Executed its 10000000 private placement offering which consisted of 3546100 units at.

Sqz Biotechnologies Nyse Sqz Quotes And News Summary Benzinga

The options each have an exercise price of 191 per share which is equal to the closing price of Viractas common stock on May 12.

. SQZ Biotechnologies NYSE. As exclusive placement agent in the offering. SQZ focused on unlocking the full potential of cell therapies for multiple therapeutic areas today announced that.

Sichenzia Ross Ference represented Aegis Capital Corp. The company has a current ratio of 574 a quick ratio of 099 and a debt-to-equity ratio of 6064. The stock has a market capitalization of C217 billion and a PE ratio of 976.

SQZ announced today that the company will present data from the first non-clinical studies of its point-of-care POC manufacturing system at the 2022 American Society for Gene and Cell Therapy ASGCT Annual Meeting on May 18. SQZ Biotechnologies names Marshelle Smith Warren as chief. SP 500 Could Drop to 3400 After Another Bear Market Rally Says Morgan Stanleys Wilson 5 Top Strategists Discuss Near-term Outlook for SP 500 and US Equities Oil prices.

The Price is Wrong. Chardan Capital analyst Geulah Livshits initiates coverage on SQZ Biotechnologies NYSESQZ with a Buy rating and announces Price Target of 17. Comparatively Adaptive Biotechnologies has a beta of 107 indicating that its.

WATERTOWN Mass June 01 2022--BUSINESS WIRE--SQZ Biotechnologies NYSE.

Claudine Adamo Stock Holdings And Net Worth In 2022 Form 4 Insider Trading Securities And Exchange Commission

Should You Sell Sqz Biotechnologies Co Sqz Stock Monday Morning